title: Grapefruit-medication interactions: forbidden fruit or avoidable consequences?
authors.affiliation: Lawson Health Research Institute, London, Ont. david.bailey@lhsc.on.ca
authors.forename: David G
authors.initials: DG
authors.lastname: Bailey
authors.forename: George
authors.initials: G
authors.lastname: Dresser
authors.forename: J Malcolm O
authors.initials: JM
authors.lastname: Arnold
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced; D001628:Beverages / Q000009:adverse effects*; D001682:Biological Availability; D001943:Breast Neoplasms / Q000139:chemically induced; D032083:Citrus paradisi / Q000009:adverse effects* / Q000378:metabolism; D051544:Cytochrome P-450 CYP3A; D065692:Cytochrome P-450 CYP3A Inhibitors; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D018565:Food-Drug Interactions / Q000502:physiology*; D005638:Fruit / Q000009:adverse effects* / Q000378:metabolism; D011564:Furocoumarins / Q000378:metabolism; D006801:Humans; D050216:Metabolic Detoxication, Phase I; D004364:Pharmaceutical Preparations / Q000378:metabolism; D012206:Rhabdomyolysis / Q000139:chemically induced; D012307:Risk Factors; D016171:Torsades de Pointes / Q000139:chemically induced
chemical_list: D065692:Cytochrome P-450 CYP3A Inhibitors; D011564:Furocoumarins; D004364:Pharmaceutical Preparations; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human